Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. - Wikidata - wikimedia - TriplyDB

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

http://www.wikidata.org/entity/Q51906755

about

Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil Early-versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.Factors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in london.Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.Predictors of long-term cognitive outcome in Alzheimer's disease OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats.Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.Prediction models for assessing long-term outcome in Alzheimer's disease: a review.Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease.Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: interim results from the long-term, large-scale J-GOLD study in Japan.Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.Top cited papers in International Psychogeriatrics: 6c. Tracking cognitive decline in Alzheimer's disease using the Mini-mental State Examination: a meta-analysis ("mini" is not necessarily trivial!).Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients.Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.The Black Book of Psychotropic Dosing and Monitoring.Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.Quantitative EEG Neurometric Analysis-Guided Neurofeedback Treatment in Dementia: 20 Cases. How Neurometric Analysis Is Important for the Treatment of Dementia and as a Biomarker?The effect of telemedicine on cognitive decline in patients with dementia.Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer's disease using 3DSRT.Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease--measured from a fixed cognitive level.Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.The usefulness of cube copying for evaluating treatment of Alzheimer's disease.The cholinergic system in the pathophysiology and treatment of Alzheimer's disease

P2860

Q26851862-576A0479-20A0-4D42-8BC4-E5A7A55CFC77 Q33408028-315D5A0F-7BEE-44CD-BD10-1CBB59CD9C57 Q33801636-3F7A3D08-9971-4704-BFD2-59F4D2BE609D Q33867858-0A472F81-4507-4742-9940-348BC49F8799 Q34233759-AA39C52A-60AE-44F7-A96A-6F518D2BF22F Q34318028-98DD16CE-186D-4917-9284-48594821367D Q34466802-DE7DAFBE-638F-4070-A27D-F9974BF0E7D9 Q34548336-EB26024B-E7A7-4C6C-95A8-D1D5D669F66A Q34549762-7CB21F66-4D01-4BBF-95CB-18D951986D98 Q35327053-36E52EAF-9A62-4F13-87DD-AFE9660AE3AB Q35579243-C6CFC571-1CAA-40A1-9D87-EE808BC51FDF Q36221014-5A7474B9-03C9-4FB6-8908-1CBFF03C4F21 Q36723409-0F8016F8-A61D-4922-B7FC-6FD22172D402 Q36998823-6964DB3D-A545-4517-92F6-D0478058CAFD Q37464280-8FA4030C-08CE-4F44-94A1-AB85BBE4D7B9 Q37690649-55085C06-9BC5-4940-9772-16F67DDF8781 Q38108098-75B5A057-CD5E-4B13-BCAE-7788D86026CD Q39388222-29BE44D3-8279-4DB2-880F-9285C2612A99 Q40793927-E062FCC1-A4D2-4E02-8E67-242C5475B49D Q41588156-1754863D-72C3-44A3-BFD0-850AC6C34549 Q43653495-B6A9628C-B42E-4E09-850E-A76A01BBBC95 Q44908766-8B4A9011-CF2F-44B2-8ECF-5A0133968AD2 Q45087048-DCF35839-DD41-43FD-8698-AC5B20D0BBFB Q47417382-A07BF3A7-1862-4B44-895C-3D19A8C02F53 Q47642128-D6A6BD26-1D1F-48C3-BF7B-16BC320D8C75 Q47786408-61CFF38A-86D7-4D89-B44B-223DB599B357 Q47962519-890F0099-4B71-4676-9EF9-70CBACDAA956 Q47970824-DEEDAE0D-4812-43DB-A370-B3AE6EAF9575 Q48356126-67FD3253-D57F-46E6-89EB-9DB59AF25577 Q49134661-3F2DDBE2-42B4-4A21-81BA-1E7E081DA36D Q50769270-129F6259-0806-4B8D-ACBC-CD414678157F Q51558760-1A00B434-C357-4729-9265-13D63F6B1B2B Q51876833-01C1AFCF-00BE-4623-9A57-F0CDAECF1886 Q57177786-3BE9906C-09BE-4120-B6C7-55BE297E6F8A

P2860

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

http://www.wikidata.org/entity/Q51906755

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Donepezil in Alzheimer's disea ...... in a routine clinical setting.

@en

Donepezil in Alzheimer's disea ...... in a routine clinical setting.

@nl

type

label

Donepezil in Alzheimer's disea ...... in a routine clinical setting.

@en

Donepezil in Alzheimer's disea ...... in a routine clinical setting.

@nl

prefLabel

Donepezil in Alzheimer's disea ...... in a routine clinical setting.

@en

Donepezil in Alzheimer's disea ...... in a routine clinical setting.

@nl

P1433

Q51906755-F64B1C6C-3569-4209-B1D7-518E902093E2

P1476

Q51906755-7B11FDCA-4808-46CE-A0F6-8AFCF1FB0992

P2093

Q51906755-267A4391-8C07-4517-B4FA-3CF2927AFACC

Q51906755-4F3668FD-6CC8-4E8D-97DC-BA98B8BEC920

Q51906755-57220ED2-C494-46F5-99BC-235676681E30

Q51906755-607FA802-AC9D-40F2-A378-57608D001377

Q51906755-86A1246F-F9AC-4871-952F-F76CADB0D369

Q51906755-8B8A7EB4-47DF-450D-9F93-EADC75608CAD

Q51906755-ADBF6374-1BD9-440C-99E1-F04C195C118C

Q51906755-D3236EED-B336-4FBA-AF6F-2A0BA55CD695

Q51906755-DBC0C1A1-8013-461B-A28F-1B9EF3382F37

Q51906755-DD318411-DF8A-463B-A30A-D95D4D7430B1

P2860

Q51906755-0DF5DC2D-FC64-47CF-9F7D-9A48889B01E7

Q51906755-0E542252-056B-4F71-929F-A0EE7CEC2A3B

Q51906755-15A710C4-B2CF-43CE-99CE-71B170A70C25

Q51906755-179085BF-CB96-4927-9AB9-FB3694E1759F

Q51906755-223B7DFD-6540-4162-80BB-8DB0B305BBDF

Q51906755-2479AF9F-05E9-49E0-B304-4610152768C1

Q51906755-294FC74D-5C79-43E5-AF79-F6F1BBD91F20

Q51906755-334B5F9F-4111-4549-BD72-A03A888CF65F

Q51906755-35E343A2-8A55-43DA-8B8D-C647B6D8E25A

Q51906755-5755E38A-A350-47B7-A9AD-46DDE1CA9B10

P304

Q51906755-97AF21AD-0C13-49FE-83AB-D48C92A5F518

P31

Q51906755-3ABA74A3-1137-4DB0-9043-6487CB2B34D6

P356

Q51906755-0E56E41B-3463-48EF-86B4-49AD75EE1CCD

P433

Q51906755-9E519179-166E-4197-B5E3-7C9FDDE884C1

P478

Q51906755-7E549017-488D-4779-AEC1-E6958C3D3AE5

P50

Q51906755-1B613A4D-94D5-4EFE-A49A-A77BF8C627DA

Q51906755-C77DFB96-74D6-4C47-B4F3-B23E5AE5D7A7

Q51906755-F60A8DCF-B673-446D-A22D-CDCC8F6289A6

P577

Q51906755-248156B2-18A2-453C-84CF-AD9AD86A6713

P5875

Q51906755-F2CFBDF3-23B2-4BD6-BCB1-C809F8CF4FF7

P698

Q51906755-BC74C453-2942-44E6-9DD1-6226C16EB34F

P356

P1433

Dementia and Geriatric Cognitive Disorders

P1476

Donepezil in Alzheimer's disea ...... in a routine clinical setting.

@en

P2093

Anders Wallin

http://www.w3.org/2001/XMLSchema#string

Asa K Wallin

http://www.w3.org/2001/XMLSchema#string

Birgitta Nasman

http://www.w3.org/2001/XMLSchema#string

Carina Wattmo

http://www.w3.org/2001/XMLSchema#string

Elisabeth Londos

http://www.w3.org/2001/XMLSchema#string

Hasse Olofsson

http://www.w3.org/2001/XMLSchema#string

Lena Kilander

http://www.w3.org/2001/XMLSchema#string

Marie Rydén

http://www.w3.org/2001/XMLSchema#string

Mikael Jonsson

http://www.w3.org/2001/XMLSchema#string

Mikaela Grut

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.

Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.

Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.

Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.

Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations.

The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease.

P304

150-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000098052

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Maria Eriksdotter

Lennart Minthon

P577

2006-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6494106

http://www.w3.org/2001/XMLSchema#string

P698

17312368

http://www.w3.org/2001/XMLSchema#string